|
Multimedia
Images, audio, and video related to cancer research
Calendar
Meetings, seminars, and press conferences focused on cancer research
Resources
Information on cancer types, treatment, prevention, and more
 Sponsored by:
The Cancer News Portal is supported by the National Cancer Institute of the National Institutes of Health. Additional information on cancer research, prevention, and treatment is available at www.cancer.gov |
Breaking News
Key: Meeting
Showing releases 1076-1100 out of 1210. << < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>
Public Release: 11-Dec-2012
 Journal of ImmunologyMoffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them. Blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improved adoptive T-cell therapy, an immunotherapy designed to suppress tumor activity. Contact: Kim Polacek
Public Release: 10-Dec-2012
Journal of Clinical OncologyEducational video helps terminal cancer patients decide whether to receive CPR Patients with terminal cancer who viewed a three-minute video demonstrating cardiopulmonary resuscitation (CPR) were less likely to indicate a preference for receiving CPR in the event of an in-hospital cardiac arrest than were patients who only listened to a verbal description of the procedure. 
Agency for Healthcare Research and Quality, Informed Medical Decisions Foundation
Contact: Sue McGreevey
Public Release: 10-Dec-2012
54th Annual Meeting of the American Society of Hematology New multiple myeloma drug shows promise in treating people with advanced disease A new oral agent under review by the U.S. Food and Drug Administration is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology Annual Meeting. The meeting is taking place Dec. 8-11, 2012 in Atlanta. Contact: Christie Corbett
Public Release: 10-Dec-2012
54th Annual Meeting of the American Society of Hematology Survey shows breakthrough medical research relies heavily on NIH funding A survey highlighting the correlation between today’s cutting edge medical research and the National Institutes of Health (NIH) funding was released today at the 54th Annual Meeting of the American Society of Hematology, the preeminent medical meeting for physicians and scientists in hematology that draws more than 20,000 attendees from around the world. The survey, representing responses from 1,040 abstract presenters from the US and abroad, demonstrates how critical NIH funding has been to the success of science and medicine. Contact: Andrea Slesinski
Public Release: 10-Dec-2012
Cancer CellTo fight incurable metastatic breast cancer, resistance must be broken One of the most frustrating truths about cancer is that even when a treatment works, it often doesn’t work for long because cancer cells find ways to resist. However, researchers reporting studies done in mice in the Dec. 10, 2012, issue of Cancer Cell, a Cell Press publication, may have a way to stay one step ahead in the case of aggressive metastatic breast cancer. Contact: Mary Beth O'Leary
Public Release: 10-Dec-2012
Proceedings of the National Academy of SciencesBiologists engineer algae to make complex anti-cancer 'designer' drug Biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug used to treat cancer. Their achievement, detailed in a paper in this week's early online issue of the Proceedings of the National Academy of Sciences, opens the door for making these and other "designer" proteins in larger quantities and much more cheaply than can now be made from mammalian cells.
National Science Foundation, Skaggs Family Foundation
Contact: Kim McDonald
Public Release: 10-Dec-2012
Journal of Clinical InvestigationResearchers identify therapeutic targets in neurofibromatosis In this issue of the Journal of Clinical Investigation, three independent groups of researchers report that MAPK hyperactivation is a critical mediator of disease pathogenesis in neurofibromatosis.
National Institutes of Health, Neurofibromatosis Preclinical Consortium, St. Baldrick's Foundation
Contact: Jillian Hurst
Public Release: 10-Dec-2012
Journal of Clinical InvestigationJCI early table of contents for Dec. 10, 2012 This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Dec. 10, 2012, in the JCI: Brown fat transplants help mice lose weight; Researchers identify therapeutic targets in neurofibromatosis; Gene regulatory network links obesity and inflammation; research identify inflammatory mediators associated with kidney stones; and many more. Contact: Jillian Hurst
Public Release: 10-Dec-2012
Journal of Clinical InvestigationStudy identifies targeted molecular therapy for untreatable NF1 tumors Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1). Scientists from Cincinnati Children's Hospital Medical Center report their findings online Dec. 10 in the Journal of Clinical Investigation, and say the data provide strong rationale for testing the therapy in clinical trials for NF1.
National Institutes of Health, NF1 Microarray Consortium, Children's Tumor Foundation
Contact: Nick Miller
Public Release: 10-Dec-2012
Journal of CommunicationInternet use can reduce fatalistic view of cancer Many Americans have fatalistic views on cancer prevention -- they believe that getting cancer is a matter of luck or fate. Recent research, published in the Journal of Communication, found that people who use the internet to inquire about their health are more likely to have a positive outlook on cancer prevention and diagnosis. Contact: John Paul Gutierrez
Public Release: 10-Dec-2012
Cell Stem CellStem cell research provides hope for infertile cancer survivors A professor at The University of Texas at San Antonio has demonstrated in rhesus monkeys that it is possible to remove testicular stem cells prior to chemotherapy, freeze them and later, after cancer treatments, transplant the cells where they can restart sperm production and restore fertility. Contact: Christi Fish
Public Release: 10-Dec-2012
American Journal of EpidemiologyCaffeinated coffee linked to lower risk of some oral cancers A new American Cancer Society study finds a strong inverse association between caffeinated coffee intake and oral/pharyngeal cancer mortality. The authors say people who drank more than four cups of caffeinated coffee per day were at about half the risk of death of these often fatal cancers compared to those who only occasionally or who never drank coffee.
American Cancer Society
Contact: David Sampson
Public Release: 10-Dec-2012
54th Annual Meeting of the American Society of Hematology Blood levels of immune protein predict risk in Hodgkin disease Dana-Farber researchers found levels galectin-1, an immunity-related protein, could be the basis of a test and potentially a targeted treatment for Hodgkin lymphoma.
Leukemia and Lymphoma Society and by the Miller Family Research Fund.
Contact: Teresa Herbert
Public Release: 10-Dec-2012
54th Annual Meeting of the American Society of Hematology Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial Dana-Farber researchers found an experimental drug combination for preventing graft-vs.-host disease was not significantly better than the standard regimen of care, but that the new combination could provide an alternative that could be preferable in certain scenarios. Contact: Teresa Herbert
Public Release: 10-Dec-2012
54th Annual Meeting of the American Society of Hematology Drug combination acts against aggressive chronic lymphocytic leukemia A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center. Contact: Scott Merville
Public Release: 10-Dec-2012
Cancer CellNovel drug therapy targets aggressive form of non-Hodgkin's lymphoma Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell -- DLBCL (ABC-DLBCL), remains a major therapeutic challenge. An international research team, led by two laboratories from Weill Cornell Medical College, has developed a new experimental drug therapy to target this aggressive form of lymphoma.
Leukemia and Lymphoma Society, Burroughs Wellcome Foundation, Chemotherapy Foundation
Contact: Lauren Woods
Public Release: 10-Dec-2012
54th Annual Meeting of the American Society of Hematology Intensified chemotherapy shows promise for children with very high risk form of leukemia Pediatric patients with B-precursor acute lymphoblastic leukemia who are likely to relapse after chemotherapy treatment can reduce those odds by receiving additional courses of chemotherapy, according to research by Dana-Farber/Children's Hospital Cancer Center investigators. Contact: Teresa Herbert
Public Release: 10-Dec-2012
Predictors of cancer disease progression improve patient selection for metastasis-directed therapy In a paper published Dec. 10 in PLOS ONE, Ludwig investigators led by Dr. Ralph Weichselbaum in collaboration with Dr. Yves Lussier at the University of Illinois were able to use microRNA expression to characterize oligometastasis and ultimately better select patients with tumor metastasis for curative interventions. This research also allows for the targeting of specific biological processes to treat patients with more advanced tumor spread.
National Institutes of Health
Contact: Rachel Steinhardt
Public Release: 10-Dec-2012
Journal of UrologyTargeted prostate biopsy has potential to improve diagnosis of prostate cancer Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers. Investigators at the University of California-Los Angeles Department of Urology have found that a new technique of targeted biopsy in a clinic setting, using local anesthesia, may improve diagnosis and aid in selecting which patients are suitable for active surveillance and which need focal therapy (noninvasive techniques for destroying small tumors within the prostate). Contact: Linda Gruner
Public Release: 10-Dec-2012
Journal of UrologyProstate cancer now detectable by imaging-guided biopsy Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.
NIH/National Cancer Institute
Contact: Kim Irwin
Public Release: 10-Dec-2012
Cancer DiscoveryUCLA cancer scientists identify liposarcoma tumors that respond to chemotherapy Using a strategy that tracks cancer cells' consumption of nucleosides, a team of researchers at UCLA's Jonsson Comprehensive Center has identified a group of liposarcoma tumors that can be imaged by PET scanning using a tracer substance known as FAC. Furthermore, they have found that these tumors are sensitive to chemotherapy. Contact: Shaun Mason
Public Release: 9-Dec-2012
54th Annual Meeting of the American Society of Hematology Engineered immune cells produce complete response in child with an aggressive pediatric leukemia By reprogramming a seven-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found that she had no evidence of cancer. Contact: Rachel Salis-Silverman
Public Release: 9-Dec-2012
54th Annual Meeting of the American Society of Hematology Leukemia patients remain in remission more than 2 years after engineered T cell therapy Nine of 12 leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania. Penn Medicine researchers will present the latest results of the trial today at the American Society of Hematology's Annual Meeting and Exposition.
Leukemia & Lymphoma Society, Alliance for Cancer Gene Therapy
Contact: Holly Auer
Public Release: 9-Dec-2012
54th Annual Meeting of the American Society of Hematology Reduced intensity regimen prior to marrow transplant better for older leukemia patients A new study led by researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute shows that preparing older acute myeloid leukemia patients for bone marrow transplants with a reduced intensity conditioning regimen appears to be associated with higher rates of disease-free survival relative to the more typical treatments usually given to such patients. Contact: Liz Bryan, Spectrum
Public Release: 9-Dec-2012
54th Annual Meeting of the American Society of HematologyMore than a third of high-risk leukemia patients respond to an experimental new drug A new drug for patients with acute myeloid leukemia marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins Kimmel Cancer Center and nine other academic medical centers around the world. Contact: Vanessa Wasta
Showing releases 1076-1100 out of 1210. << < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>
|
Search News Releases
|
|||||||||||||||||||||||||
 |
||||
|
|
 |
|